Q-omics provides the consensus-scored MYBPC1 profile across patient tissues and cancer cell-line models. MYBPC1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MYBPC1 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, MYBPC1 RNA expression shows 10,146 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight UVM, and HNSC as cancer lineages where MYBPC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYBPC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYBPC1 survival associations across molecular data types. MYBPC1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYBPC1 RNA expression–survival associations across cancer types. High MYBPC1 expression shows unfavorable associations in UVM, CHOL and KICH, but favorable associations in BRCA, OV and ACC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify UVM as the clearest survival context for MYBPC1 RNA expression.
This table summarizes MYBPC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MYBPC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYBPC1 shows lower tumor expression in HNSC, BRCA and UCEC and higher tumor expression in LIHC, PRAD and LUSC. The HNSC box plot shows higher MYBPC1 RNA expression in normal versus tumor tissue (log2 FC = −3.336, t-test p < 0.001).
This table shows molecular features associated with MYBPC1 in patient tissues and cancer cell lines. In patient samples, MYBPC1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, MYBPC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
